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Abstract:  
Background: The World Health Organization has reported more than 31,186,000 confirmed cases of 
coronavirus disease-19 (COVID-19), including 962,343 deaths, worldwide as on September 21, 2020. The 
current COVID-19 pandemic is affecting clinical research activities in most parts of the world. The focus on 
developing  a vaccine for SARS-CoV-2 and the treatment of COVID-19 is, in fact, disrupting many upcoming 
and/or ongoing clinical trials on other diseases around the globe. On March 18, 2020, the United States Food 
and Drug Administration (FDA) issued an updated guideline for the conduct of clinical trials during the current 
health emergency situation. The potential challenges, such as social distancing and quarantines, result in study 
participants’ inaccessibility and trial personnel for in-person scheduled study visits and/or follow-up. Due to the 
sudden onset and wide-spread impact of COVID-19, its influence on the management of clinical trials and 
research necessitates urgent attention. Therefore, our systematic review of the literature aims to assess the impact 
of the COVID-19 pandemic on the conduction of clinical trials and research. The search for the relevant articles 
for review included the keywords "COVID-19” AND "clinical trial" in PubMed, MEDLINE, Embase, Google 
scholar and Google electronic databases. Key findings include: delaying subject enrollment and operational gaps 
in most ongoing clinical trials, which in turn has a negative impact on trial programmes and data integrity. 
Globally, most sites conducting clinical trials other than COVID-19 are experiencing a delay in timelines and a 
complete halt of operations in lieu of this pandemic, thus affecting clinical research outcomes. 
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Introduction 
The World Health Organization (WHO) declared coronavirus 
disease-19 (COVID-19) a global public health emergency in 
late January 2020.  COVID-19 is a newly identified coronavirus 
strain that initially infected people in Wuhan, China [1]. Due to 
the rapid spread of the infection in China, and other Asian 
countries, the respective governments have implemented a 
range of public health preventive measures. The West had 
experienced the spread of the virus before the Asian countries 
could control its transmission [2]. Globally, as of the 21st of 
September 2020, there have been 31,186,000 confirmed cases 
of COVID-19, including 962,343 deaths, reported by the WHO. 
The various preventive measures adopted by different countries 
included travel restrictions (domestic or international), social 
distancing, with the closure of schools, restrictions on mass 
gatherings, quarantine, adherence to personal hygiene, use of 
face masks and, the implementation of infection control 
measures in healthcare settings [3]. In combination with the 
lockdown of commercial activities and movement, these 
restrictions helped to control the spread of infection. However, 
these global preventive strategies pose unprecedented 
challenges and obstacles for clinical research; consequently, 
many clinical research organisations do not initiate new trials, 
facing difficulties in recruiting new subjects and experiencing 
lower follow-up rates in the ongoing clinical trials. 
The monitoring of patients is possibly the most significant 
ongoing challenge that the performing trials sites are currently 
facing.  On the 18th of March 2020, the US (United States) Food 
and Drug Administration (FDA) issued new guidelines for 
clinical trials’ conduction during this critical situation. The 
significant obstacles encountered are ‘created’ by social 
distancing and quarantine measures which forbid interaction 
between the study participants and trial personnel for study 
visits and scheduled follow-up. The  clinical trial’s integrity is 
questionable due to the spread of COVID-19 infection to trial 
participants and staff, which influences trial outcomes with 
increasing likelihood of trial dropout. Finally, there may be 
limited access to beds, clinical tests, and Personal Protective 
Equipment (PPE) as these might be diverted to clinical care 
facilities and staff to deal with COVID-19 patients. 
Due to the sudden onset and widespread impact of COVID-19, 
its influence on managing clinical trials and research remains 
undetermined [4-9]. Therefore, this systematic review of 
research the literature aims to assess the global impact of the 
COVID-19 pandemic on the conduction of clinical trials and 
research. 
 
 
Methodology  
The current systematic review process was performed and 
reported following the guidelines of the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
(PRISMA)[10]. The protocol of this systematic review is 
registered in the Open Science Framework (OSF# 
osf.io/2b5zk). 
Literature Searches 
This study’s eligibility criteria were articles primarily focusing 
on the thematic interface between "COVID-19" AND "clinical 
trial", which were fully indexed in PubMed, MEDLINE and 
Embase. Furthermore, in order to search for additional eligible 
records, a similar search strategy was adequately deployed in 
Google Scholar and Google. The keywords used for searches 
were variants representing the term coronavirus such as "2019-
nCoV"; "2020-nCov"; " 2019-20 coronavirus*"; " 2019-2020 
coronavirus*"; "SARS-CoV-2", AND “clinical trial” 
mentioned either in the title or in the abstract. We have included 
and screened all published articles highlighted the impact of 
COVID-19 on clinical trials and clinical research as there is a 
paucity of literature on this topic due to the sudden onset and 
evolving nature of the COVID-19 pandemic. 
Inclusion/Exclusion Criteria 
The included studies were (a) published original research, (b) 
written in English; (c) completed and published between 
January 1, 2020, and September 05, 2020; (d) highlighted the 
impact of COVID-19 on clinical trial; (e) focused on patients 
from the global listed countries.  
The decision to include or exclude a study was based on the 
availability of information regarding the impact of COVID-19 
on the clinical trial. The relevant studies available as full texts 
for review were further considered in this review; whereas, 
abstracts without full texts were excluded. 
Data Extraction 
The results of the searches of the databases were initially 
scanned for appropriate titles of the studies. The selected titles 
were then screened for the abstracts as well as full texts, and 
those that met the eligibility requirements were considered for 
final selection. All the literature evaluation (including abstracts 
and full-text articles or reports) was independently conducted 
by four researchers (BS, MA, IB, and BR). The extracted data 
mainly included the study’s origin, authors, sample size, study 
population, design, settings/location, period and outcome. 
Methodology Quality Assessment 
All systematic reviews incorporate a process of critique or 
appraisal of the research evidence. The purpose of this appraisal 
is to assess the methodological quality of a study and to 
determine the extent to which a study has addressed the 
possibility of bias in its design, conduct and analysis. We used 
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the Studies The Joanna Briggs Institute (JBI) Critical Appraisal 
Checklist for Analytical Cross Sectional studies [11]. 
 
Results 
The literature searches generated a total of 554 million articles, 
of which 553,999,915 were either review articles or duplicate 
publications that were excluded from the initial screening. 
Therefore, only the relevant titles and abstracts underwent a 
detailed assessment, and later on, 81 articles were excluded 
from the review process that finally resulted in six relevant 
articles (four research reports and two articles) included in this 
review. We used the PRISMA diagram to depict the flow of 
information through the different phases of the systematic 
review, it maps out the number of records identified, included 
and excluded (Figure 1) [10]. Extracted details for six of the 
studies are presented in Table 1 [4-9]. The score consists of 
eight domains, for figure elaboration and analysis we used 
RevMan version 5.3 (The Cochrane Collaboration, 
Copenhagen, Denmark) as shown in Figure 2 & 3.  Overall 
quality was high in the studies found; nevertheless, the domains 
of confounding and strategies to deal with confounding factors 
were deficient in most of the studies because of presence of 
some difference between the subjects. 
Characteristics of the studies 
On April 23, 2020, the Medidata technology and solutions, a 
global platform that supports clinical trials, performed an 
electronic survey of 9,952 staff at various trial investigator sites 
[5]. This survey had a low response rate of 10.3% as a total of 
1,030 participants responded to at least one question of the 
survey. Most respondents were from the US (North America; 
58.3%) followed by Asia (23.8%), Europe (8.1%), South & 
Central America (7.1%). and the Middle East/Africa (2.7%). 
The vast majority of respondents were study coordinators 
(73%), followed by investigators (11.0%), site 
managers/directors (5.4%), clinical nurses (4.1%) and others 
(6.3%). The survey results showed that the ability to conduct 
ongoing clinical trials during the COVID-19 pandemic had 
affected 69% of respondents, whereas 78% mentioned that this 
situation affected the initiation of new trials. The primary 
concerns mentioned by these survey respondents that hamper 
their ability were subject enrollment (3.7%); recruitment of 
patients (3.7%); financial losses due to study cancellation 
(3.4%); and financial implication from delayed endpoints 
(3.3%), which were computed with a weighted average. Apart 
from this, other concerns included: accessibility of patients to 
the trial site (3.1%), health concern of the trial team members 
(3.1%), and the necessity for COVID-19 screening (3.9%). 
Overall, respondents were very concerned about subject 
enrollment and recruitment as more than half mentioned 
concerns regarding these issues. 
Currently, the worldwide impact of COVID-19 on the 
conduction of clinical trials is being monitored by Medidata. 
The initial insights and facts about the impact of COVID-19 
were reported on March 23rd, 2020, which was subsequently 
updated in April and May 2020. These facts demonstrated a 
decline in new subject enrollment in many ongoing clinical 
trials, highlighing the growing impact of this emergency on 
clinical trials at both regional and international levels with 
continued regulations for social distancing and guidelines 
recommending movement restriction outside of the home. In 
comparison to the pre-COVID-19 baseline  (October 31),  
globally there is around 30% decrease in enrollment of new 
subjects entering trials by the end of June which was previously 
higher in April, 2020 (~70% drop). Currently, within different 
geographic regions, a marked variability has been observed 
regarding the extent and timing of recovery of patients due to 
continued fluctuation in the COVID-19 cases, and adoption of 
regulations over the time [8]. By the end of July 2020, there is 
an improvement in new subject enrollment in clinical trials per 
study-site worldwide with  around -30% for the month of June 
in comparison to -6% at baseline (pre-COVID-19). Howevre, 
the negative effects of COVID-19 on  new patients enrollment 
in clinical trials is expected to continue at different times and 
varying degree throughout the world which remains understated 
[9]. 
The most recent report was released on May 15th, 2020 (Table 
2), which demonstrated a sharp decline in the average number 
of new subject enrollment (74%) in clinical trials per study-site 
year-on-year (YoY) in the initial two weeks of May 2020 as 
compared to the same period in 2019. This impact on the 
average number of new subject enrollment for the initial two 
weeks of May 2020 is comparable to the previous month 
(April), showing a continued impact of COVID-19 on the new 
enrollment and clinical trial activities as a whole [5].  
Table 3  highlighted the special considerations regarding 
different phases of clinical trial conduction in the coronavirus 
pandemic. In summary, mitigation efforts such as self-isolation 
and inaccessibility of health care facilities during pandemic 
interferes with all aspects of clinical trials at various levels. So, 
the delivery of intervention and collection of outcome data 
should requires thoughtful considerations. Finally, conduction 
of clinical trial activities may require suitable protocol 
amendments to ensure the rights, safety, and wellbeing of the 
study participants as well as the research staff. 
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Figure 1:  The PRISMA flow diagram for the systematic Review detailing the database searches, the number of 
 abstracts screened and the full texts retrieved. 
 
 
 
Figure 2:  Risk of bias graph: 
 
 
 
Review authors' judgements about each risk of bias item presented as percentages across all included studies. 
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Figure 3:  Risk of bias summary  
 
 
Review authors' judgements about each risk of bias item for each included study. 
 
 
Table 1:  Main characteristics of the studies 
 
Author, year Origin Study 
duration 
Study 
design  
Sample size Sampling Main findings  
Medidata, 
2020 [4] 
Multicenter April 23rd, to 
April 29th, 
2020 
Cross-
Sectional 
 
 
 
1,030 subjects Convenience 
sampling 
For 69% of respondents, COVID-19 has 
affected their ability to conduct ongoing trials, 
while 78% believe that COVID-19 has 
impacted the initiation of new trials. The top 
four concerns based on the weighted average 
of the answers were: ability to enroll patients 
(3.73); ability to recruit patients (3.66); 
financial implications for cancelled studies 
(3.42); and financial implication from delayed 
milestones (3.29). 
Medidata, 
2020 [5] 
Multicenter March, April 
and the first 
two weeks of 
May 
Cross-
Sectional  
 
4,667 studies 
and 186,807 
study-sites 
Convenience 
sampling 
A 74% decrease in the average number of new 
patients entering trials per study-site year-
over-year during the first two weeks of May 
compared to last year. Shows the pandemic 
continues to have an effect on trial activity and 
new patients entering trials. 
Upadhaya, 
2020 [6] 
Multicenter March 23rd  
and April 3rd  
2020 
Cross-
Sectional  
 
36 subjects  Convenience 
sampling 
Patient enrolment in active oncology clinical 
trials was negatively affected at the time of the 
survey. Asia [60%], United States [20%] and 
Europe [14%] were continuing to enrol 
patients at the usual rate.  
Waterhouse, 
2020 [7] 
USA March 24th to 
30th, 2020 
Cross-
Sectional  
32 subjects Convenience 
sampling 
Over half of the respondents (54.8%) observed 
a decrease in patient’s willingness to come to 
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Table 2: Impact of COVID-19 on new subject enrollment in clinical trials 
 
Variables Variables YoYD* March 2020 Vs 
March 2019 
YoYD* April 2020 Vs 
April 2019 
YoYD* May 2020 Vs 
May 2019 
All countries,  
All Therapeutic areas 
 -65% -79% -74% 
Asia China -68% -33% -49% 
 India -84% -97% -95% 
 Japan -44% -69% -72% 
 South Korea -61% -42% -54% 
Europe France -68% -81% -76% 
 Germany -33% -77% -81% 
 Italy -53% -49% -65% 
 Spain -68% -82% -68% 
 United States -66% -83% -73% 
 United Kingdom -80% -95% -100% 
Therapeutic areas Cardiovascular -69% -95% -91% 
 CNS** -68% -76% -75% 
 Endocrine  -64% -91% -89% 
 ID/ Anti infectives -47% -66% -52% 
 Oncology -48% -60% -58% 
 Respiratory -34% -86% -81% 
* YoYD = year-on-year difference ; ** CNS = central nervous system 
Source: COVID-19 and Clinical Trials: The Medidata Perspective, Release 5.0 [5] 
 
 
 their site and cited the staff time needed to 
conduct telehealth visits as a significant 
challenge. 51.6% noted that limited 
availability of ancillary services was 
challenging. Time spent in discussion with 
sponsors, CROs, and IRBs about modifying 
trial procedures also presented a challenge for 
51.6% participants. 
Medidata, 
2020 [8] 
Multicenter June 15, July 
13, 2020 
Cross-
Sectional 
 
 
 
1,030 subjects Convenience 
sampling 
In comparison to the pre- COVID-19 baseline  
(October 31),  globally there is around 30% 
decrease in enrollment of new subjects 
entering trials by the end of June which was 
previously higher in April, 2020 (~70% drop). 
Currently, within different geographic regions, 
a marked variability has been observed 
regarding the extent and timing of recovery of 
patients due to continued fluctuation in the 
COVID-19 cases, and adoption of regulations 
over the time. 
Medidata, 
2020 [9] 
Multicenter July 13 - 
August 12, 
2020 
Cross-
Sectional  
 
5,089 studies 
and 194,506 
study sites. 
Convenience 
sampling 
By the end of July 2020, there is an 
improvement in new subject enrollment in 
clinical trials per study-site worldwide with  
around -30% for the month of June in 
comparison to -6% at baseline (pre-COVID-
19). The negative effects of COVID-19 on  
new patients enrollment in clinical trials is 
expected to continue at different times and 
varying degree throughout the world which is 
likely understated. 
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Table 3: Special considerations for conducting clinical trials in the Coronavirus Pandemic 
Discovery/ Recruitment Enrollment/ Participation Completion/ Follow-up 
Coronavirus mitigation efforts (self-
isolation) interfere with all aspects of 
clinical trials at multiple levels. 
Efforts and resources should be dedicated 
to support continuing randomized trials 
using creative and thoughtful methods and 
proactive planning. 
Effective communication by research 
staff is likely to help protect against 
dropout or nonadherence during the 
pandemic. 
Interruption of supply chains and 
monitoring of clinical trials are 
additional obstacles. 
Research staff should keep participants 
informed about the effects of the 
coronavirus pandemic on their trial 
participation. 
Outcomes should be prioritized, and trial 
operations should be virtualized, if 
possible. 
Ethics committees must apply rigorous 
standards to authorize research in 
accordance with the principles of justice, 
equity and solidarity. 
Participants should be informed of 
necessary changes in protocol and how this 
may affect the risk associated with study 
participation.  
Alternative methods for measuring 
primary outcomes should be prepared and 
protocols modified to facilitate collection 
of self-reported or medical record data. 
Conduction of clinical trials may require 
modifications to ensure the rights, safety, 
and wellbeing of participants as well as 
medical staff. 
Delivery of intervention requires 
thoughtful consideration, emphasizing 
safety and feasibility under coronavirus 
restrictions. 
Questionnaires previously collected in-
person can be converted to telephone 
administration. 
 
Discontinue randomized trials that do 
not have an immediate clear benefit to 
enrolled participants. 
Adapting protocols to facilitate continued 
intervention adherence and outcome 
measurement. 
When feasible and safe, objective 
outcomes could be collected at home. 
 
Discussion  
The ongoing COVID-19 pandemic has a potentially negative 
impact on the management of clinical trials, which may 
compromise the scientific integrity of data and may raise 
concerns for patient safety. Moreover, there is an unprecedented 
operational burden on trials’ conduction as there is limited 
access to trial activities and investigations of novel therapies or 
interventions for various diseases, particularly involving 
vulnerable populations [12,13]. The FDA issued guidelines for 
conducting clinical trials focusing on this current pandemic 
which should be followed by research teams currently involved 
in clinical trial programs [12].  
Randomised clinical trials (RCTs) provide the highest quality 
of evidence for developing newer therapies or interventions to 
treat challenging diseases, thus improving the quality of life 
(QoL). Until March 2020, the ClinicalTrials.gov, an 
international clinical trial registry, documented a total of 
262,366 ongoing RCTs, most of which are registered for 
investigating a drug or biological intervention (n=146,420), 
followed by trials on behavioural studies (n=85,045) and based 
on surgical/device interventions (n=61,351) [14]. 
Issues in management clinical trials: current perspectives: 
For universities and the pharmaceutical industry, useful and 
timely management of clinical trial operations is crucial due to 
the substantial financial investment (US$20–50 million per 
trial). Furthermore, large trial centres usually run multiple trials 
at any given point of time, enrolling thousands of patients at 
various sites worldwide. Therefore, this pandemic disrupts 
operational planning, decision-making, and creates operational 
gaps that can significantly affect the financial cost and patient 
safety with interruption of treatment leading to potential harm. 
To date, many institutions and organisations have already 
paused their clinical trials. There are several critical challenges 
in the current pandemic which include: (a) limited accessibility 
of clinics mainly for essential or critical visits, (b) there is 
difficulty in recruiting homebound patients, or others are also 
reluctant to visit clinics, (c) currently trial operations may 
expose the staff or patients to the risk of acquiring the infection, 
(d) continuation of the trial may lead to a high drop-out rate, (e) 
inability to meet logistical trial obligations by sponsors as well 
as contractors (i.e., delivery of investigational products, PPE or 
site monitoring), and (f) deviation from the study timelines may 
affect data integrity due to delayed assessment and monitoring. 
Notably, COVID-19 prevents several institutions from 
continuing their previously existing trial activities. Disruption 
of trial programmes has resource, ethical, and care implications.  
In order to continue the trial operations, it is necessary to follow 
the regulatory guidelines and regularly review the current 
infection trend, oversight of lockdown policies and travel 
restrictions, future prediction of COVID-19 and understanding 
key risk indicators. Based on these trends, appropriate 
recommendations and policies should be followed at the trial 
sites, and risk-based decision making should use evidence from 
both epidemiologists and health policy-makers. These decisions 
regarding trials may consider changing study sites, extending 
programmes, and amendment of planned trial closure, 
monitoring and screening activities, site access, and, where 
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appropriate, application of machine learning-driven forecasting 
models. As these changes require time and resources, so it is 
crucial to have robust risk/issue trackers together with the better 
symbiosis between operational- and strategic-level decision-
making. 
Notably, the concept of telemedicine exists for the past two 
decades. However, its integration into clinical practice has 
specific administrative and bureaucratic challenges, mainly 
involving the cost of implementation and reimbursement that is 
far beyond the conceptualization or technological shortfalls 
[15]. However, the use of telemedicine approaches have 
become progressively more popular and acceptable by health 
authorities, medical doctors and patients after the current 
pandemic, and positive outcomes from associated intervention 
have been intensively described and reported worldwide 
[16,17]. 
We suggest that adopting telemedicine in the clinical research 
settings, assessing the global impact of decisions, developing 
contingency plans, providing additional financial support, 
greater flexibility and understanding may be useful to help solve 
this problem. Clinical trials necessitate colossal investment in 
terms of finance, logistics and other resources (including 
participants’ time). Similar to the previous pandemics, the 
impact of the COVID-19 on clinical trials will hopefully be 
short-lived; meanwhile, to maximize the public health benefits 
of existing trials, we need creativity and persistence in these 
unprecedented times. 
Guidelines to be followed on clinical research analysis and 
conduct during COVID-19 pandemic:     
Participants must be self-isolated, and research staff needs to 
work remotely to avoid direct contact. A framework for 
detection, recording, assessment, and reporting of all procedural 
deviations is required, and the appropriate board should be in 
place to monitor the progress of the clinical trial site(s). All 
protocol deviations that could lead to severe risk for the patient 
must be reported. The trial must always be conducted in-line 
with the Good Clinical Practices (GCP) guidelines. 
Monitoring activities should be reassessed to ensure the safety 
of study participants. Besides, some processes may have to be 
modified, such as electronic alternatives for signatures that may 
have to be considered. As administrative personnel may not be 
able to meet study teams or answer direct calls personally, the 
use of teleconferencing and voice mails during the pandemic 
will be useful.  
Isolation/quarantine criteria can lead to deviations intended to 
remove a research participant's immediate apparent threats. For 
example, if the participant is unable to attend the treatment 
appointment, and if the only re-scheduling date available is 
outside of the study visit period duration, no research protocol 
or doses should be missed. In this case, a missed dose or 
procedure for the maintenance of the security and welfare of the 
subject should not cause any potential harm. So, the health and 
safety of the participants in the study should be maintained and 
prioritized. Also, participants must be aware of the 
risks/changes associated with the study protocol that could 
affect their well-being. All participants affected by a COVID19-
related study disruption should be documented by a unique 
participant identifier and description of how the individual’s 
participation was altered. In the case of a visit to the clinical trial 
site, the researchers may have to assess whether alternate safety 
assessment measures are feasible if participants are unable to 
come to research sites as set out in the study protocol. 
Alternative methods may include telephonic conversation or the 
use of telemedicine for virtual visits or alternative sites for 
care/collecting study data. Alternative locations may need to be 
considered for imaging and laboratory testing as per study 
protocol. In the case of alternative monitoring, careful 
documentation will be required to obtain the reason, how 
information has been collected, what data has been collected, 
who has provided the information; how the information sources 
have been verified and why. No amendments to the study 
protocol are required. 
Researchers are encouraged to consider whether they should 
hold all the study procedures or part of it during the pandemic. 
This can refer to all procedures or part of a study. Maybe it is 
necessary to hold registration, study visits, collect or analysis of 
data, etc. It is understood that the cessation of the treatment of 
a patient might not be unsafe or may seriously affect project 
performance. So, the decision to place a hold on a particular 
study needs to be made in consultation with the institutional 
governing body to safeguard the study participants’ and 
departments’ needs. [18, 19] 
Finally, in order to efficiently address the anticipated 
circumstances by data monitoring committees during the 
pandemic, special provisions should be placed. For instance, 
data assessment regarding the benefits and risks of interventions 
for COVID-19 requires faster communication during health 
emergencies [20]. This could be possible through virtual 
meetings with the help of encrypted communication to protect 
data integrity. Also, most essential measures regarding benefits 
and risks should be given preference for data capture and 
reporting to the data monitoring committee for efficient and 
timely oversight in the COVID-19 setting. 
Expert opinion 
Clinical trials are of paramount importance for the advancement 
and development of novel treatment interventions. The ultimate 
goal of such trials and studies is to ensure the best quality patient 
care with the highest and most favourable outcome, whilst 
decreasing the cost and suffering of (a burden to) the recipient. 
Such endeavours are vital to the medical community. For the 
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functioning of a robust medical system wherein discoveries, 
drugs and technology can be applied to the system from the top 
tier and eventually diffuse out to primary and satellite care 
centres to ensure the best care for all.  
Historically, clinical trials have usually been a laborious, 
expensive, and difficult task to undertake under normal 
circumstances; however, trials under the unprecedented 
COVID-19 conditions have indeed suffered its consequences.  
The often complicated design and intricate nature of clinical 
trials mean the likelihood of derailment is high. A cohort of 
multiple external factors has to be controlled and maintained to 
ensure the sanctity of the data as well as the integrity of the trial. 
All the criteria mentioned above are nullified by a pandemic 
such as COVID-19. 
For the commencement of a new clinical trial or even the 
maintenance of an existing trial, funding is a priority in order to 
drive it to completion. COVID-19 severely impeded funding of 
non-COVID-19 related trials as the acquisition of a cure for the 
virus took centre stage for international funding bodies. Over 
and above the funding issue, the need to tightly monitor trial 
participants and subsequently ensure their safety through such 
a pandemic proved detrimental to many ongoing studies, or 
those recently started. The statistics show a sharp decline in the 
enrolment of new members for trials.  
Clinical trials did not only compete for funding under COVID-
19 conditions but simultaneously had to cope with lockdown 
regulations that made accessibility of the study participants 
virtually impossible. The fact that data from the ongoing studies 
will be incomplete or will have gaps could lead to either 
shutting down the trial, a severe delay (and hence additional 
cost), or the need to re-start the trial. The ramifications of 
COVID-19 causing such a massive international dearth in the 
commencement of new trials and the continuation of non-
COVID-19 trials will not be evident in the immediate future. 
However, the impact thereof will become evident as the time 
lost will add up to years lost in research in the broader spectrum. 
COVID-19 and its deleterious effects on trials call for a possible 
re-structuring of how trials are conducted. A feasible, practical 
and scientifically sound alternative to conventional trial studies 
is needed. The alternative will need to ensure scientific integrity 
but will also need to balance the needs of the parties involved 
to overcome various difficulties due to external factors. A 
solution to trials and research as well as time and funding lost 
during lockdown due to COVID-19 must be addressed, 
ensuring scientific breakthroughs and the development of new 
technology is not hindered or delayed. The lives of millions of 
patients are dependent on the continual clinical breakthroughs 
and discoveries which are produced by these trials. 
 
 
Conclusion 
The COVID-19 pandemic has resulted in a series of public 
health policies that have crippled the healthcare systems of 
many countries. This situation hugely impacted the study 
participants, care providers, researchers, trial sponsors, and 
research organizations concerning clinical trials. This pandemic 
has a substantial impact on the trial sites as they experience 
difficulty in the continuation of trial activities which eventually 
hampers the progress of the trial and delays study timelines. 
Most sites are struggling due to delayed subject enrollment, 
shortfalls in monitoring, and risks of compromised data 
integrity, and this situation has negatively impacted the 
initiation of future trials as well. Researchers are also concerned 
regarding the delay or cancellations of trials in this situation, 
which will have a financial impact on research organizations 
and human resources. According to one survey, about two-
thirds of the respondents have stopped or will soon halt subject 
enrollment in ongoing clinical trials, one-third halted 
randomization, and fifty percent of respondents are delaying or 
planning to delay the studies. Therefore, using dynamic, 
proactive strategies and a framework for decision-making and 
risk assessment is needed to overcome these challenges in 
conducting clinical trials. Adopting new approaches and 
understanding the key risk indicators will help managers 
support trial sites with flexibility and ingenuity. For instance, 
switching patient site visits to new-trial virtualization, and 
telemedicine to interact with patients will help manage current 
clinical trials also beneficial for the post-pandemic era. 
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